Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddhartha Dutta, Vamshi Sarangi et al.|The Lancet|2021Cited by 361
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trialRaches Ella, Siddarth Reddy, William C. Blackwelder et al.|medRxiv|2021Cited by 80
CD28 Homodimer Interface Mimetic Peptide Acts as a Preventive and Therapeutic Agent in Models of Severe Bacterial Sepsis and Gram-Negative Bacterial PeritonitisGirish Ramachandran, Steven M. Opal, Raymond Kaempfer et al.|The Journal of Infectious Diseases|2014Cited by 41